Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip 100
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:

Vietnam Bans Two Hepatitis B Vaccines After Deaths Of Babies

This article was originally published in PharmAsia News

  • News

Executive Summary

Vietnam's Ministry of Health ordered a ban on a pair of vaccines against hepatitis B after at least two babies died following injections. Samples of the vaccine have been sent to the Institute of Drug Quality Control for testing, the director of the ministry's pharmaceutical management department said. The drugs reportedly had been made by the National Institute of Hygiene and Epidemiology and its Vibiotech subsidiary. The ministry, which is looking into the two deaths, plans to ask LG of South Korea and Vaccine and Biological Products of Vietnam to inspect their vaccines for hepatitis vaccine and for diphtheria, pertussis and tetanus. (Click here for more
Table

View full table

Advertisement
Advertisement
Tags:
UsernamePublicRestriction

Register

SC067820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By